Karyopharm Therapeutics (NASDAQ:KPTI) Cut to Hold at StockNews.com

StockNews.com downgraded shares of Karyopharm Therapeutics (NASDAQ:KPTI) from a buy rating to a hold rating in a research report report published on Wednesday morning.

Several other analysts have also weighed in on KPTI. Royal Bank of Canada reiterated an “outperform” rating and set a $3.00 target price on shares of Karyopharm Therapeutics in a research note on Wednesday, August 7th. HC Wainwright reiterated a “buy” rating and set a $7.00 price objective on shares of Karyopharm Therapeutics in a research note on Friday, November 1st. Robert W. Baird decreased their target price on Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating for the company in a research note on Wednesday, August 7th. Finally, Piper Sandler upped their target price on Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an “overweight” rating in a report on Wednesday. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $5.00.

Karyopharm Therapeutics Stock Performance

NASDAQ:KPTI opened at $0.88 on Wednesday. The company has a market capitalization of $109.88 million, a price-to-earnings ratio of -0.77 and a beta of 0.16. Karyopharm Therapeutics has a one year low of $0.62 and a one year high of $1.95. The stock has a 50-day simple moving average of $0.81 and a 200 day simple moving average of $0.90.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Tuesday, November 5th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.01. The firm had revenue of $38.78 million for the quarter, compared to the consensus estimate of $37.86 million. During the same period in the prior year, the business earned ($0.30) EPS. On average, equities research analysts forecast that Karyopharm Therapeutics will post -0.95 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Point72 DIFC Ltd acquired a new position in shares of Karyopharm Therapeutics during the second quarter worth approximately $31,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Karyopharm Therapeutics during the 2nd quarter worth $143,000. Acadian Asset Management LLC bought a new position in shares of Karyopharm Therapeutics in the second quarter worth $167,000. Exchange Traded Concepts LLC grew its stake in shares of Karyopharm Therapeutics by 34.9% in the third quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company’s stock worth $182,000 after purchasing an additional 56,613 shares in the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of Karyopharm Therapeutics during the second quarter valued at $494,000. Institutional investors own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).